Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

Andreas Koster; Bruce Spiess; Derek P. Chew; Thomas Krabatsch; Luc Tambeur; Abe Deanda; Roland Hetzer; Hermann Kuppe; Nicholas G. Smedira; A. Michael Lincoff

doi:10.1016/j.amjcard.2003.10.021

Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

Andreas Koster, Bruce Spiess, Derek P. Chew, Thomas Krabatsch, Luc Tambeur, Abe Deanda, Roland Hetzer, Hermann Kuppe, Nicholas G. Smedira, A. Michael Lincoff

Heart And Vascular Health

Research output: Contribution to journal › Article › peer-review

110 Citations (Scopus)

Abstract

We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

Original language	English
Pages (from-to)	356-359
Number of pages	4
Journal	American Journal of Cardiology
Volume	93
Issue number	3
DOIs	https://doi.org/10.1016/j.amjcard.2003.10.021
Publication status	Published or Issued - 1 Feb 2004

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2003.10.021

Cite this

Koster, A., Spiess, B., Chew, D. P., Krabatsch, T., Tambeur, L., Deanda, A., Hetzer, R., Kuppe, H., Smedira, N. G., & Lincoff, A. M. (2004). Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. American Journal of Cardiology, 93(3), 356-359. https://doi.org/10.1016/j.amjcard.2003.10.021

@article{5ebfc1ce7d8046c5b59d20f4dbabb8b3,

title = "Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",

abstract = "We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.",

author = "Andreas Koster and Bruce Spiess and Chew, {Derek P.} and Thomas Krabatsch and Luc Tambeur and Abe Deanda and Roland Hetzer and Hermann Kuppe and Smedira, {Nicholas G.} and Lincoff, {A. Michael}",

note = "Funding Information: This study was supported by The Medicines Company, Parsippany, New Jersey. ",

year = "2004",

month = feb,

day = "1",

doi = "10.1016/j.amjcard.2003.10.021",

language = "English",

volume = "93",

pages = "356--359",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "3",

}

Koster, A, Spiess, B, Chew, DP, Krabatsch, T, Tambeur, L, Deanda, A, Hetzer, R, Kuppe, H, Smedira, NG & Lincoff, AM 2004, 'Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting', American Journal of Cardiology, vol. 93, no. 3, pp. 356-359. https://doi.org/10.1016/j.amjcard.2003.10.021

TY - JOUR

T1 - Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

AU - Koster, Andreas

AU - Spiess, Bruce

AU - Chew, Derek P.

AU - Krabatsch, Thomas

AU - Tambeur, Luc

AU - Deanda, Abe

AU - Hetzer, Roland

AU - Kuppe, Hermann

AU - Smedira, Nicholas G.

AU - Lincoff, A. Michael

N1 - Funding Information: This study was supported by The Medicines Company, Parsippany, New Jersey.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

AB - We investigated the use of bivalirudin as an anticoagulant therapy during cardiopulmonary bypass in 20 patients who underwent coronary artery bypass grafting. Primary end points consisted of clinical outcome data, whereas secondary end points focused on blood loss, transfusions, pharmacokinetics, and monitoring. Our data provide the first evidence of clinical feasibility of anticoagulation with bivalirudin during cardiopulmonary bypass.

UR - http://www.scopus.com/inward/record.url?scp=10744225946&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2003.10.021

DO - 10.1016/j.amjcard.2003.10.021

M3 - Article

C2 - 14759391

AN - SCOPUS:10744225946

SN - 0002-9149

VL - 93

SP - 356

EP - 359

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 3

ER -

Effectiveness of Bivalirudin as a replacement for Heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this